1921
Volume 81, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

From 1987 to 1994, we enrolled 500 subjects completing 2-year WHO multiple drug therapy (MDT) for multibacillary leprosy in a prospective relapse study. Relapse was defined as new skin lesions and an increase in the bacterial index (BI) ≥ 2+ (≥ 100×) at any single slit-skin smear site. At the study end in 2006, follow-up was 6,401 subject-years, a mean of 12.8 years/subject. We observed 23 relapses, 6–16 years after MDT (mean, 10.5 years; 95% confidence interval [CI], 9.2–11.8), peaking in Years 11–12 (> 1%/year). The cumulative risk was 6.6% (95% CI, 5.0–8.2%). In a subset of 181 subjects with pre-MDT average BI ≥ 4+, 11 relapses occurred (cumulative risk, 10.1%). In mouse footpad assays, from relapsed subjects were rifampin and clofazimine sensitive. Taken together, the data suggest relapses are related to activation of dormant organisms (persisters) not killed by MDT rather than new infection.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2009.09-0189
2009-11-01
2017-05-28
Loading full text...

Full text loading...

/deliver/fulltext/14761645/81/5/0810895.html?itemId=/content/journals/10.4269/ajtmh.2009.09-0189&mimeType=html&fmt=ahah

References

  1. Britton WJ, Lockwood DN, 2004. Leprosy. Lancet 363: 1209–1219.
  2. Dasananjali K, Schreuder PA, Pirayavaraporn C, 1997. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984–1996. Int J Lepr Other Mycobact Dis 65: 28–36.
  3. Gebre S, Saunderson P, Byass P, 2000. Relapses after fixed duration multiple drug therapy: the AMFES cohort. Lepr Rev 71: 325–331.
  4. Jamet P, Ji B, 1995. Relapse after long-term follow up of multibacillary patients treated by WHO multidrug regimen. Marchoux Chemotherapy Study Group. Int J Lepr Other Mycobact Dis 63: 195–201.
  5. Desikan KV, Sundaresh P, Tulasidas I, Rao PV, 2008. An 8–12 year follow-up of highly bacillated Indian leprosy patients treated with WHO multidrug therapy. Lepr Rev 79: 303–310.
  6. Poojabylaiah M, Marne RB, Varikkodan R, Bala N, Dandakeri S, Martis J, 2008. Relapses in multibacillary leprosy patients after multidrug therapy. Lepr Rev 79: 320–324.
  7. Cellona RV, Balagon MF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, Topolski R, Gelber RH, Walsh DS, 2003. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr Other Mycobact Dis 71: 308–319.
  8. Sehgal VN, Joginder, 1990. Slit-skin smear in leprosy. Int J Dermatol 29: 9–16.
  9. Ridley DS, Jopling WH, 1966. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 34: 255–273.
  10. Villahermosa LG, Fajardo TT Jr, Abalos RM, Cellona RV, Balagon MV, Dela Cruz EC, Tan EV, Walsh GP, Walsh DS, 2004. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multidrug therapy for multibacillary leprosy. Am J Trop Med Hyg 70: 197–200.
  11. Lee ET, 1992. Statistical Methods for Survival Analysis Data. New York: Wiley.
  12. Dasananjali K, 1996. Relapse of leprosy after multidrug therapy. J Med Assoc Thai 79: 635–639.
  13. Gelber RH, Balagon MV, Cellona RV, 2004. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis 72: 493–500.
  14. Baohong J, 2001. Does there exist a subgroup of MB patients at greater risk of relapse after MDT? Lepr Rev 72: 3–7.
  15. Pattyn SR, Dockx P, Rollier MT, Rollier R, Saerens EJ, 1976. Mycobacterium leprae persisters after treatment with dapsone and rifampicin. Int J Lepr Other Mycobact Dis 44: 154–158.
  16. Sehgal VN, Jain S, Charya SN, 1996. Persisters, relapse (reactivation), drug resistance and multidrug therapy (MDT): uniform diagnostic guidelines for leprosy are needed. J Dermatol 23: 905–907.
  17. Balagon MV, Cellona RV, Fajardo TT Jr, Abalos RM, Walsh DS, Villahermosa LG, Tan EV, dela Cruz EC, Walsh GP, 1999. Detection of new leprosy cases at a walk-in skin clinic in Cebu City, Philippines, highlights surveillance. Int J Dermatol 38: 796–797.
  18. Arbiser JL, Moschella SL, 1995. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol 32: 241–247.
  19. Fajardo TT, Abalos RM, dela Cruz EC, Villahermosa LG, Walsh DS, Cellona RV, Balagon MV, Tan EV, Walsh GP, 1999. Clofazimine therapy for lepromatous leprosy: a historical perspective. Int J Dermatol 38: 70–74.
  20. Villahermosa LG, Walsh DS, Fajardo TT Jr, Abalos RM, dela Cruz EC, Veerasubramanian P, Walsh GP, 1999. Resolution of lepromatous leprosy after a short course of amoxicillin/clavulanic acid, followed by ofloxacin and clofazimine. Int J Dermatol 38: 558–560.
  21. Constant-Desportes M, Guelpa-Lauras CC, Carolina JC, Leoture A, Grosset JH, Sansarricq H, 1991. A case of relapse with drug-susceptible M. leprae after multidrug therapy. Int J Lepr Other Mycobact Dis 59: 242–247.
  22. Saunderson P, Bizuneh E, Leekassa R, 2008. Absence of late relapse in a cohort of patients with multibacillary leprosy (Abstract O-131). 17th International Leprosy Congress, January 30–February 4, 2008, Hyderabad, India.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2009.09-0189
Loading
/content/journals/10.4269/ajtmh.2009.09-0189
Loading

Data & Media loading...

  • Received : 14 Apr 2009
  • Accepted : 14 Jul 2009

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error